Akeso, Inc. announced it will present more than 40 clinical studies of its oncology portfolio at the 2026 ASCO Annual Meeting, including a Late-Breaking Abstract in the Plenary Session. Key data will focus on its bispecific antibodies cadonilimab and ivonescimab, with pivotal Phase III results from the HARMONi-6 study on advanced squamous non-small cell lung cancer. Additional presentations cover various cancers, showcasing Akeso's innovative antibody platform and its potential impact on cancer treatment. This highlights Akeso's growing role in global biopharmaceutical innovation.
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...
Between May 18 and May 24, major public firms like Strategy and BitMine halted Bitcoin and Ethereum purchases, focusing instead on bonds and capital management. Despite a $687 million drop in stablecoin liquidity and reduced decentralized exchange tr...
Pendle Finance has focused its co-incentive program exclusively on limit orders, leading to limit orders making up 71% of total swap volume and nearly doubling monthly trading activity. Users placing unfilled short yield token limit orders within tar...
High Arctic Overseas Holdings Corp. announced it will resume drilling operations in Papua New Guinea starting July 2026, following the renewal of its drilling services contract effective May 1, 2026, for two years with an option to extend. The compan...
Georgia and Tether launched GEL₮, a stablecoin pegged to the Georgian lari, aiming to speed up cross-border payments and reduce costs using blockchain technology. This partnership marks a shift from traditional state-run digital currencies to private...
